Antithymocyte globulin is widely used before haematopoietic transplantation with HLA-matched unrelated donors or mismatched relatives to prevent rejection and graft-versus-host disease (GVHD). However, optimal dosage is still under debate. Thirty-one consecutive children, mainly with haematological malignancies, were transplanted in a single institution with such donors, selected by HLA-A -B compatibility by serology and DRB1* by DNA typing. Antithymocyte globulin (Thymoglobuline; Sangstat) was infused at days ؊3, ؊2, ؊1. 
patients have an HLA-identical sibling and because the registries of volunteer donors are growing. However, severe graft-versus-host disease (GVHD) increases morbidity and mortality for haematopoietic transplantation from alternative donors when compared to HLA-matched siblings. [1] [2] [3] [4] Pre-graft serotherapy directed against lymphocytes has been demonstrated to reduce the risk of severe GVHD. [5] [6] [7] Different types of pre-graft serotherapy have been used including monoclonal antibodies such as OKT3, or Campath 1G anti-CD52, or rabbit or horse polyclonal antibodies directed against thymocytes or T lymphocytes. 2, [5] [6] [7] [8] The type of antibody used during the conditioning regimen affects the rate of GVHD, infection and relapse. 8 A recent study reported that 15 mg/kg, but not 7.5 mg/kg, of rabbit antithymocyte globulin (ATG), reduces the incidence of grade III-IV acute GVHD. However, the outcome of the graft was unchanged, since opportunistic infections were more frequent. 9 Immune reconstitution of lymphocyte subsets after different doses of ATG has never been compared.
We transplanted 31 children using haematopoietic stem cells obtained from matched unrelated donors or mismatched relatives between June 1995 and February 1999, mainly for haematologic malignancies. GVHD prophylaxis consisted of rabbit antithymocyte globulin (Thymoglobuline; SangStat, Lyon, France) at days Ϫ3, Ϫ2, Ϫ1, cyclosporine A, short-course methotrexate and steroids. 10 The total dose of Thymoglobuline varied over time. The first 12 patients received 1 unit (25 mg) per 10 kg body weight per day ('low-dose group'). As unpublished results suggested a lower incidence of GVHD with higher dose, the following 15 patients received 1 unit for 5 kg body weight per day ('high-dose group'). Due to the high incidence of viral infections in the high-dose group, the last four patients were included in the low-dose group. We retrospectively analysed immune reconstitution of these two groups.
Patients and methods

Patients
Between June 1995 and February 1999, 31 consecutive children received a bone marrow graft as first transplant from an HLA-matched unrelated donor or an HLA-mismatched relative in Hôpital Robert-Debré. The total dose of Thymoglobuline for each patient is reported in Table 1 . The first 12 and the last four patients received a median of 7.5 mg/kg (2.5 to 10.5: ' low-dose group'), and the other 15 a median of 15.5 mg/kg (14.4 to 19.4: 'high-dose group').
Diseases and conditioning regimen
Underlying diseases were diverse in this paediatric series, although similar in the two groups. Among haematological malignancies, three patients (20%) in the low-dose group and six (46%) in the high-dose group had advanced disease (relapse, third or later remission) (P = 0.23, Table 1 ). Leukemic patients under 3 years of age received busulfan, whereas those of 4 years or more received total body irradiation. This was combined with high-dose cytarabine and melphalan for acute lymphoblastic leukaemia (ALL) patients, and with cyclophosphamide for acute myeloid leukaemia (AML) patients.
Donors, graft and HLA typing
All patients received unmanipulated marrow grafts from matched unrelated donors or partially mismatched relatives. Donors were selected on the basis of identity for HLA-A and -B defined by standard complement-dependent microlymphocytotoxicity assay, and of HLA-DRB1* defined at the sequence level by sequence-specific primers polymerase chain reaction (PCR-SSP) (Dynal, Compiègne, France). For the purpose of the study, HLA typing of donors and recipients was retrospectively performed at sequence level for A*, B*, Cw and DQB1* for those patients for whom sufficient pre-transplant DNA was available (PCR-SSP; Dynal or Bionobis, Montfort-l'Amaury, France).
Post-transplant GVHD prophylaxis and supportive therapy
Post-transplant GVHD prophylaxis was uniform. Cyclosporine A was begun intravenously at day Ϫ1 at the end of the last Thymoglobuline infusion to target a whole-blood level between 200 and 250 ng/ml. Cyclosporine was shifted to the oral route between day +20 and day +30, and slowly tapered after day +90, with elective cessation at day +180. Methotrexate was given according to the 'ultra-short' timing: 15 mg/m 2 at day +1, and 10 mg/m 2 at days +3 and +6. Ten mg/m 2 leucovorin was given 12 h after each injection of methotrexate. Prednisone was systematically given from day +7: 0.5 mg/kg/day from day +7 to day +14, 1 mg/kg/day from day +15 to day +28, and then slowly tapered to be discontinued at day +180. Supportive therapy was given according to the institutional standard.
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Outcome measures
Acute GVHD was diagnosed from clinical symptoms and/or biopsies from skin, oral mucosa, gut or liver. Grading was assigned from 0 to IV according to standard criteria. 12 Chronic GVHD was diagnosed from clinical symptoms and/or biopsies from skin or mucosa. It was classified as limited or extensive according to published criteria. 13 Engraftment was considered to have occurred when the absolute neutrophil count had reached 0.5 ϫ 10 9 /l for at least 3 consecutive days. Transplant-related mortality (TRM) was defined as death, in continuous complete remission for haematological malignancy. Relapse was defined as more than 5% blasts in the bone marrow or presence of any leukaemic cells at another site. Post-transplant lymphoproliferative disorder (PTLD) was diagnosed as already published, 14 on the basis of a finding of diffuse hyperplasia characterised by invasion of blood vessels and other organ structures, with disorganisation of the nodal structure in lymph nodes, and if pathological investigation was not possible, by a raised EBV viral load, fever and lymph node enlargement. Adenovirus infection was diagnosed when diarrhoea or pulmonary infiltrates were accompanied by adenovirus in the stool, urine or blood.
CD4
+ , CD3 + , CD8 + , CD19 + and CD16 + CD56 + cells were counted by flow cytometry, using commercially available antibodies. These counts were performed every 2 months up to 6 months, every 3 months up to 12 months and every 6 months thereafter.
Statistical analysis
Analysis was performed using 1 February 2002 as the cutoff date for follow-up. For short-range events such as relapse, GVHD and opportunistic infections, group proportions were compared using the two-sided Fisher's exact test. The probability of TRM, survival, disease-free survival, time to 200 CD19 + , 1000 CD3 + and 100 CD4 + cells/mm 3 , were calculated according to the Kaplan-Meier method and compared by the two-tailed log-rank test. Ninety-five per cent confidence intervals (95%CI) were calculated using the method developed by Dorey and Korn. 15 The end-points for CD19
+ and CD3 + /mm 3 were chosen because they correspond to the 5th percentile of normal children over 2 years of age. 16 The value of 100 CD4 + cells/mm 3 was retained because, in children, post-transplant potentially life-threatening opportunistic infections occur mainly below this level. 4 No patient was lost to followup. For disease-free survival, event was defined as death, rejection of the graft or relapse of the malignant disease. For each of these end-points, data were censored at the time of analysis or at the occurrence of a competing risk factor. These competing risk factors for each end-point were as follows: death for GVHD; relapse for TRM; death, relapse, rejection and donor lymphocytes infusion for time to 100 CD4 + and 1000 CD3 + cells; death, relapse, rejection, donor lymphocyte infusion and PTLD for time to 200 CD19 + cells.
Results
Retrospective HLA compatibility analysis
Retrospective analysis of HLA compatibility using molecular biology techniques was possible for 25 patients. Results are reported in Table 2 . Match in GVHD direction on the 10 studied loci (A*, B*, Cw*, DRB1*, DQB1*) was fulfilled for three out of 11 patients (27%) in the low-dose group, and eight out of 14 patients (57%) in the high-dose group (P = 0.23).
Engraftment and GVHD
All patients but one in the high-dose group engrafted (Table  2) . One patient (patient 227) in the high-dose group rejected her graft 4 days after initial engraftment. Six out of 16 patients (38%) in the low-dose group experienced acute grade III-IV GVHD, and one out of 15 (7%) in the highdose group (P = 0.08). Eleven patients in the low-dose group, and 12 in the high-dose group were evaluable for chronic GVHD. Two limited and one extensive chronic GVHD occurred in the low-dose group, whereas no patient in the high-dose group experienced chronic GVHD (P = 0.09; Table 2 ).
Bone Marrow Transplantation
Immune reconstitution
Median time to reach 100 CD4 + /mm 3 was 4 months in the low-dose group and 8 months in the high-dose group (P = 0.03, Figure 1a) . Median time to reach 1000 CD3 + cells/mm 3 was 7 months in the low-dose group. No patient in the high-dose group reached this value before being censored (Figure 1b) . Median time to reach 200 CD19 + /mm 3 was 8 months in the low-dose group compared to 16 months in the high-dose group (P = 0.02), and only two patients reached this end-point in the high-dose group (Figure 1c) . CD8 + and CD56 + /CD16 + cell reconstitution was comparable between the two groups (data not shown).
Opportunistic infections and relapse
Two low-dose patients (13%) and nine high-dose patients (60%) experienced PTLD or adenovirus infection (P = 0.009, Table 2 ). Among haematological malignancies, there were three relapses in the low-dose group (20%), and four in the high-dose group (31%; P = 0.67).
Outcome
Median follow-up was 36 months. Overall, 16 patients died. Cumulative TRM (95%CI) was 0.31 (0.19-0.45) in the low-dose group, and 0.46 (0.26-0.64) in the high-dose group (P = 0.67). Survival rates were 0.52 (0.31-0.70) and 0.40 (0.21-0.56) respectively (P = 0.39). Disease-free survival rate was 0.56 (0.34-0.72) in the low-dose group, and 0.27 (0.12-0.39) in the high-dose group (P = 0.08).
Discussion
We compared immune reconstitution in two groups of children receiving two different doses of ATG before unrelated or mismatched BMT. This is the first such report, to our knowledge. Because early patient censorship is usual in this context, we used the Kaplan-Meier method and the logrank test to compare lymphocyte subset reconstitution in all patients, not only in the long-term survivors. Although obtained from a limited number of patients, results suggest that CD19
+ , CD3 + and CD4 + cell reconstitution after unrelated bone marrow transplantation in children is slower after 15 mg/kg of pre-transplant Thymoglobuline than after 7.5 mg/kg. They also suggest, as reported by others, that opportunistic life-threatening infections are more frequent after 15 mg/kg.
CD4
+ reconstitution appeared significantly delayed in high-dose patients. This accounts for delayed CD3
+ reconstitution, as CD8
+ reconstitution seemed not to be affected by Thymoglobuline dose. CD4
+ reconstitution is crucial to control post-transplant opportunistic infections, since such potentially life-threatening infections occur mainly in transplanted children with fewer than 100 CD4 + cells/mm 3 . 4 The impaired CD4
+ T cell recovery in high-dose patients is thus in accordance with the higher rate of severe opportunistic infections seen in that group.
The high-dose group was slightly better HLA-matched than was the low-dose group. We have no explanation other ADV = adenovirus infection; PTLD = post-transplant lymphoproliferative disorder; DLI = donor lymphocyte infusion; aCD20 = CD20 monoclonal antibody; CDF = cidofovir. than chance for this difference. Since HLA mismatch plays a negative role in immune reconstitution, 4, 17 this difference argues against selection bias to explain delayed CD4 + reconstitution in the high-dose group. The higher rate of GVHD in the low-dose group should also have reduced this difference, as it is well known that GVHD delays immune reconstitution. 17, 18 Immune reconstitution was probably not affected by the use of post-transplant steroids, since the same regimen was used in the two groups, and the addition of steroids to cyclosporine and methotrexate was found to be unrelated to transplant outcome in a recent study. 19 Therefore, the delayed immune reconstitution observed can best be related to Thymoglobuline dose. Moreover, the Bone Marrow Transplantation delayed immune reconstitution fits with previous reports of persistence of rabbit IgG more than 100 days after transplant at levels correlated with pre-graft dosage, 7 of the lower rate of grade III-IV GVHD after 15 mg/kg but not after 7.5 mg/kg, and of a higher rate of opportunistic infections after 15 mg/kg ATG. 9 There were more life-threatening opportunistic infections in the high-dose group. We have already reported elsewhere in the treatment of PTLD these high-dose patients with donor lymphocyte infusions and anti-CD20 monoclonal antibodies, and the treatment of adenovirus infection with cidofovir. 11, 14 Of the seven patients with adenovirus in the high-dose group, six received cidofovir, and five of them recovered from adenovirus infection. All three patients with PTLD in the high-dose group received anti-CD20 antibodies and/or donor lymphocyte infusions, and recovered from their PTLD. The only patient with adenovirus in the low-dose group who did not receive cidofovir died of adenovirus infection. The only patient with PTLD in the lowdose group was diagnosed post-mortem as cerebral PTLD. He had not received anti-CD20 monoclonal antibodies or DLI. Thus, the treatment of opportunistic infections was more aggressive in the high-dose group. This may explain our observation that the higher frequency of opportunistic infections in the high-dose group did not translate into decreased survival.
Immune reconstitution of our high-dose patients is comparable to that of unrelated T cell-depleted transplants in children, in which median time to 200 CD19 + /mm 3 is 24 months, to 1000 CD3 + /mm 3 is 12 months and to 100 CD4 + /mm 3 is 6 months. 4, 17 In our low-dose patients, time to reach normal values of B and T cells is comparable to that of related transplants in children, T cell-depleted or not. For these groups, median time to 200 CD19 + /mm 3 is 3 to 8 months (8 months in our low-dose group) and to 1000 CD3 + /mm 3 is 8 or 9 months (7 months in our lowdose group). 18, 20 There is, however, a large difference in the period at risk of life-threatening opportunistic infections, as median time to 100 CD4 + /mm 3 in our low-dose patients is 4 months compared to 1 month in children receiving related transplants. 18, 20 Our data suggest that a dose of 7.5 mg/kg ATG provides return to normal levels of B and T cells comparable to that of related transplants. However, even with that dose, the period at risk for life-threatening opportunistic infections is four times longer than in related transplants. To reduce the ensemble of risk of GVHD, relapse and opportunistic infections, new approaches are needed to prevent GVHD without impairing immune reconstitution in unrelated or HLA mismatched transplants.
